Global Impact of COVID-19 on Stroke Care

SVIN COVID-19 global registry

Et al.

Let us know how access to this document benefits you.
Follow this and additional works at: https://escholarship.umassmed.edu/covid19

Part of the Cardiovascular Diseases Commons, Clinical Epidemiology Commons, Epidemiology Commons, Health Services Administration Commons, Health Services Research Commons, Infectious Disease Commons, Nervous System Diseases Commons, and the Virus Diseases Commons

Repository Citation
SVIN COVID-19 global registry, Nogueira R, Puri AS, Kuhn AL, Nguyen T. (2021). Global Impact of COVID-19 on Stroke Care. COVID-19 Publications by UMMS Authors. https://doi.org/10.1177/1747493021991652. Retrieved from https://escholarship.umassmed.edu/covid19/173

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
This material is brought to you by eScholarship@UMassChan. It has been accepted for inclusion in COVID-19 Publications by UMMS Authors by an authorized administrator of eScholarship@UMassChan. For more information, please contact Lisa.Palmer@umassmed.edu.
Global impact of COVID-19 on stroke care

SVIN COVID-19 global registry

Abstract

Background: The COVID-19 pandemic led to profound changes in the organization of health care systems worldwide.

Aims: We sought to measure the global impact of the COVID-19 pandemic on the volumes for mechanical thrombectomy, stroke, and intracranial hemorrhage hospitalizations over a three-month period at the height of the pandemic (1 March–31 May 2020) compared with two control three-month periods (immediately preceding and one year prior).

Methods: Retrospective, observational, international study, across 6 continents, 40 countries, and 187 comprehensive stroke centers. The diagnoses were identified by their ICD-10 codes and/or classifications in stroke databases at participating centers.

Results: The hospitalization volumes for any stroke, intracranial hemorrhage, and mechanical thrombectomy were 26,699, 4002, and 5191 in the three months immediately before versus 21,576, 3540, and 4533 during the first three pandemic months, representing declines of 19.2% (95%CI, −19.7 to −18.7), 11.5% (95%CI, −12.6 to −10.6), and 12.7% (95%CI, −13.6 to −11.8), respectively. The decreases were noted across centers with high, mid, and low COVID-19 hospitalization burden, and also across high, mid, and low volume stroke/mechanical thrombectomy centers. High-volume COVID-19 centers (−20.5%) had greater declines in mechanical thrombectomy volumes than mid- (−10.1%) and low-volume (−8.7%) centers (p < 0.0001). There was a 1.5% stroke rate across 54,366 COVID-19 hospitalizations. SARS-CoV-2 infection was noted in 3.9% (784/20,250) of all stroke admissions.

Conclusion: The COVID-19 pandemic was associated with a global decline in the volume of overall stroke hospitalizations, mechanical thrombectomy procedures, and intracranial hemorrhage admission volumes. Despite geographic variations, these volume reductions were observed regardless of COVID-19 hospitalization burden and pre-pandemic stroke/mechanical thrombectomy volumes.

Keywords

COVID-19, stroke care, acute ischemic stroke, mechanical thrombectomy, intracranial hemorrhage, epidemiology

Received: 16 December 2020; accepted: 8 January 2021

Introduction

In December 2019, a novel highly pathogenic virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), caused an infectious disease involving multiple organ systems termed coronavirus disease 2019 (COVID-19). COVID-19 holds a unique balance between high transmissibility and low-to-moderate morbidity and mortality that has led to a nearly universal spread with devastating consequences worldwide. On 11 March 2020, the World Health Organization declared a global pandemic as COVID-19 hospitalizations and emergency medical system activations increased. As a potential consequence of its neurotropism as well as the inflammatory, immunological, and coagulation disorders, COVID-19 has been reported in association with a broad array of neurological disorders including encephalitis, Guillain-Barré syndrome, seizures, ischemic, and hemorrhagic strokes. Some groups reported an increase in cryptogenic strokes involving young patients with SARS-CoV-2 infection, possibly in association with endothelial inflammation and thrombotic diathesis. Others reported a decline in the rates of stroke hospitalizations and the proportion of patients receiving
reperfusion therapies (intravenous thrombolysis (IVT) and/or mechanical thrombectomy (MT)) for acute ischemic stroke (AIS). Notably, many of these studies originated from global epicenters for the pandemic supporting the notion that the indirect or collateral damage of COVID-19 on systems of care has had a greater impact on stroke patients than the viral infection itself.\textsuperscript{3,5,8–12} However, most of these reports were limited to regional or country-specific analyses, and thus, the extent to which the COVID-19 outbreak has impacted global stroke systems of care has not been previously assessed. Importantly, given the profound benefit of MT in AIS, the global public health impact of such declines, if confirmed, adds to the devastation caused by COVID-19.

**Aims and hypotheses**

We conducted an international, observational study on the impact of the COVID-19 pandemic on stroke care at the height of the COVID-19 pandemic. Our primary aim was to evaluate the effect of COVID-19 on stroke care as measured by the changes in volumes for overall stroke hospitalizations, ischemic stroke/transient ischemic attacks (TIA) admissions, ICH admissions, and MT procedures across the pre-pandemic and pandemic periods in a multinational pool of comprehensive stroke centers (CSC). The study compared the three initial months of the pandemic (1 March 2020–31 May 2020) with (1) the immediately preceding months (December 2019–February 2020 for overall volume and November 2019–February 2020 for monthly volume) as the primary analysis and (2) the equivalent three months in the previous year (1 March 2019–30 May 2019) as the secondary analysis. The reason for this analytic hierarchy was an a priori expectation that the volumes for both stroke admissions and MT procedures would increase over time due to the growing evidence supporting the broader utilization of MT.\textsuperscript{13–15} While the primary analysis provided a realistic picture of stroke care utilization prior to COVID-19, the secondary analysis allowed for the assessment for potential seasonal variations.\textsuperscript{16}

We hypothesized that in the face of the pandemic’s strain on healthcare infrastructure, (1) a reduction in all four aforementioned measurements of stroke care would take place over the pandemic, (2) centers with higher COVID-19 inpatient volumes would report greater decreases in stroke admissions and MT procedure volumes, (3) the degree of decline in stroke admissions and MT procedure volumes would be less profound in high-volume compared to low-volume stroke centers, and (4) a geographic variation would exist in the intensity of decline in stroke care.

**Methods**

Data are available upon request to the corresponding author.

**Study design**

This was a cross-sectional, observational, retrospective study evaluating monthly and weekly volumes of consecutive patients hospitalized with a diagnosis of COVID-19, stroke, MT, and ICH. The diagnoses were identified by their related ICD-10 codes (primary, secondary, or tertiary discharge codes) and/or classifications in stroke databases at participating centers.

**Setting and participants**

Data were collected from collaborators of the Society of Vascular and Interventional Neurology, the Middle East North Africa Stroke and Interventional Neurotherapies Organization, the Japan Society of Vascular and Interventional Neurology, and academic partners from 6 continents, 40 countries, and 187 CSCs. To reduce bias, only centers providing the full dataset required for any given analysis were included in that specific analysis. Centers were screened for potential confounders that could explain unexpected changes in volumes. One center in Vietnam was excluded from the MT secondary analysis due to an abrupt increase in volume attributed to the purchase of automated imaging software. One center in Brazil was excluded from the stroke admission analysis because it became the designated center for stroke patients, resulting in tripling of their volumes.

**Study variables and outcomes measures**

The overall and mean monthly volumes for stroke hospitalizations, admissions for ischemic stroke/TIA, and admissions for ICH and MT procedures were compared across the pandemic and pre-pandemic periods for the overall population and across the low, mid, and high volume strata based on mean monthly volume tertiles for COVID-19 hospitalizations ($\leq 10.6$ vs. $>10.6–103.6$ vs. $>103.6$ COVID-19 admissions/month), stroke admissions ($\leq 46.2$ vs. $>46.2–78.4$ vs. $>78.4$ stroke admissions/month), and MT interventions ($\leq 4.8$ vs. $>4.8$ to $11.4$ vs. $>11.4$ procedures/month).

**Statistical analysis**

We first compared overall hospital volumes for stroke admissions (overall stroke, ischemic, and ICH) and MT procedures between the pre-pandemic and the pandemic period. For this analysis, the percentage change in the number of admissions or procedures between the

---

*International Journal of Stroke, 0(0)*
two time periods was calculated. The three-month pre-pandemic period was restricted to three months before the pandemic (1 December 2019–29 February 2020) to keep it consistent with the three months during the COVID-19 pandemic group (1 March 2020–31 May 2020). The 95% confidence intervals for percentage change were calculated using the Wilson procedure without continuity correction. The analyses were repeated within each tier (low, mid, and high) of centers classified based on COVID-19 hospitalizations, stroke admissions, and MT procedures. The relative percentage change in overall volume between low, mid, and high-volume centers was tested using the z-test of proportion. We also looked at relative change in overall volume by continent.

In the second analysis, we compared monthly hospital volumes (admissions or procedures/hospital/month) for our outcome of interests between the pre-pandemic and the pandemic period. For the pre-pandemic period, for each hospital, the monthly hospital volume was calculated from November 2019 to February 2020 and compared to the monthly hospital volume during the pandemic period (1 March 2020–31 May 2020). The data were analyzed in a mixed design using a repeated-measures analysis of variance (PROC MIXED analysis in SAS) to account for the paired data structure and potential covariates. The auto-regressive, compound symmetrical, and unstructured variance-covariance matrix structures were analyzed for the best model determined by Akaike’s Information Criterion. The unstructured matrix was the best fit and used for most analyses. The monthly hospital volume analysis was adjusted for peak COVID-19 volume for each country and the continent. Estimated marginal means were calculated using the LSMEANS statement in PROC MIXED. Similar to the overall volume analysis, monthly volume analysis was repeated within low, mid, and high tier of centers based on their COVID-19 hospitalizations, stroke admissions, and MT procedures as well as by the continent.

Finally, for our secondary objective, we compared the relative change in overall volume and change in monthly hospital volume during the COVID-19 pandemic and corresponding three months from 2019 (1 March 2019–31 May 2019). All data were analyzed using SAS version 9.4 (SAS Institute), and the significance level was set at a p-value of <0.05.

**Funding and ethics**

This was an investigator-initiated project with no funding. The first and last authors wrote the first draft of the manuscript with subsequent input of all co-authors. The institutional review boards from the coordinating sites (Emory University and Boston University) considered that the investigators did not have access to protected health information, and thus no IRB oversight was required since the study did not meet the federal description of human subject research. This study is reported in accordance with the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) statement.

**Results**

A total of 16,141, 26,699, and 21,576 stroke hospitalizations (overall n = 64,416) and 3397, 5191, and 4533 MT procedures (overall n = 13,121) were included across the three-month prior year, three-month immediately pre-pandemic, and three-month pandemic periods, respectively.

**Overall stroke hospitalization volumes**

In the primary analysis of overall volume, stroke hospitalization volumes were 26,699 admissions in the three months immediately before compared to 21,576 admissions during the pandemic, representing a 19.2% (95%CI, −19.7 to −18.7, N = 121 sites) drop, Table 1. The stroke hospitalization decline had a geographic variation: Asia, −20.5% (95%CI, −21.2 to −19.8); North America, −20.6% (95%CI, −21.4 to −19.7); Europe, −11.2% (95%CI, −12.3 to −10.1); South America, −15.9% (95%CI, −17.9 to −14.0); Oceania, −11.6% (95%CI, −14.4 to −9.3); Africa, −48.1% (95%CI, −55.8 to −40.5), Table S1. In an analysis of monthly volume, after adjustment for peak COVID-19 volume by country and continent, the number of hospitalizations for stroke/month/hospital (adjusted mean (SE)) declined from 76.4 (12.3) pre-pandemic to 64.2 (12.0) during the pandemic (p < 0.0001), Table 1.

**Mechanical thrombectomy procedural volumes**

MT volume data was represented by 176 centers in the primary analysis with 5191 procedures in the three months immediately preceding compared to 4533 procedures during the first three months of the pandemic, representing a 12.7% (95%CI, −13.6 to −11.8) decline, Table 2. The volume reduction varied: Asia, −9.8% (95%CI, −11.3 to −8.4); North America, −14.5% (95%CI, −16.2 to −12.9); Europe, −14.4% (95%CI, −16.4 to −12.6); South America, −12.4% (95%CI, −19.0 to −7.9); Oceania, −9.4% (95%CI, −13.4 to −6.5); Africa, −21.2% (95%CI, −37.8 to −10.7), Table S2. The adjusted mean (SE) number of MT procedures/month/center decreased from 10.9 (1.3) pre-pandemic to 9.8 (1.3) during the pandemic (p < 0.0001), Table 2. There were 120 centers that
### Table 1. Stroke admissions overall and monthly volumes immediately before and during the COVID-19 pandemic

| Overall volume | Monthly volumea |
|----------------|-----------------|
|                | Change % (95%CI) | N | Immediately before | During COVID-19 | p     |
| N              | n1              | n2 | Adjusted mean (SE) |                |       |
| Overall        | 119             | 26,699 | 21,576 | –19.2 (–19.7 – –18.7) | 121 | 76.4 (12.3) | 64.2 (12.0) | <0.0001 |
| Hospital COVID-19 volumeb |
| Low            | 38              | 7612 | 6654 | –12.6 (–13.4 – –11.9) | 38 | 62.4 (31.4) | 53.9 (30.7) | 0.002   |
| Mid            | 31              | 7495 | 6008 | –19.8 (–20.8 – –19.0) | 34 | 84.8 (10.5) | 71.0 (8.7) | 0.002   |
| High           | 30              | 7163 | 5534 | –22.7 (–23.7 – –21.8) | 33 | 90.1 (9.8) | 72.9 (9.3) | <0.0001 |
| Hospital stroke volumec |
| Low            | 40              | 3536 | 3003 | –15.1 (–16.3 – –13.9) | 40 | 28.7 (2.6) | 24.5 (2.5) | <0.0001 |
| Mid            | 37              | 6804 | 5609 | –17.6 (–18.5 – –16.7) | 40 | 62.7 (2.7) | 53.1 (3.3) | <0.0001 |
| High           | 37              | 14,994 | 12,400 | –17.3 (–17.9 – –16.7) | 41 | 134.1 (21.6) | 111.6 (20.8) | <0.0001 |

N: number of hospitals; n1: number of admissions immediately before COVID-19 pandemic; n2: number of admissions during COVID-19 pandemic; CI: confidence interval; SE: standard error.

Note: The n1 is based on 3 months before (December 2019–February 2020) COVID-19 pandemic.

aThe monthly volume analysis is adjusted for peak COVID-19 volume for each country and the continent.
b p: low vs. mid ≤ 0.0001; low vs. high ≤ 0.0001; mid vs. high ≤ 0.0001.
c p: low vs. mid = 0.001; low vs. high = 0.002; mid vs. high = 0.588.

### Table 2. Mechanical thrombectomy overall and monthly volumes immediately before and during the COVID-19 pandemic

| Overall volume | Monthly volumea |
|----------------|-----------------|
|                | Change % (95%CI) | N | Immediately before | During COVID-19 | p     |
| N              | n1              | n2 | Adjusted mean (SE) |                |       |
| Overall        | 176             | 5191 | 4533 | –12.7 (–13.6 – –11.8) | 173 | 10.9 (1.3) | 9.8 (1.3) | <0.0001 |
| Hospital COVID-19 volumeb |
| Low            | 44              | 952 | 869 | –8.7 (–10.7 – –7.1) | 44 | 11.2 (3.6) | 10.5 (3.5) | 0.044   |
| Mid            | 45              | 1370 | 1232 | –10.1 (–11.8 – –8.6) | 45 | 11.7 (1.2) | 10.8 (1.2) | 0.004   |
| High           | 45              | 1602 | 1273 | –20.5 (–22.6 – –18.6) | 46 | 7.8 (2.2) | 5.7 (2.2) | <0.0001 |
| Hospital MT volumec |
| Low            | 59              | 459 | 412 | –10.2 (–13.4 – –7.8) | 60 | 2.6 (0.36) | 2.3 (0.36) | 0.082   |
| Mid            | 55              | 1294 | 1092 | –15.6 (–17.7 – –13.7) | 55 | 8.1 (0.46) | 7.0 (0.50) | 0.0002 |
| High           | 58              | 3432 | 3029 | –11.7 (–12.9 – –10.7) | 58 | 18.8 (1.8) | 16.8 (1.7) | 0.0002 |

N: number of hospitals; n1: number of procedures immediately before COVID-19 pandemic; n2: number of procedures during COVID-19 pandemic; CI: confidence interval; SE: standard error; MT: mechanical thrombectomy.

Note: The n1 is based on three months before (December 2019–February 2020) COVID-19 pandemic.

aThe monthly volume analysis is adjusted for peak COVID-19 volume for each country and the continent.
b p: low vs. mid = 0.259; low vs. high ≤ 0.0001; mid vs. high ≤ 0.0001.
c p: low vs. mid = 0.004; low vs. high = 0.345; mid vs. high = 0.0003.
reported concomitant monthly data on stroke admission and MT volume. The adjusted mean (SE) monthly proportion of MT relative to stroke admissions remained stable across the pre-pandemic and pandemic periods (17.8 (2.2)% vs. 18.5 (2.2)%, respectively; p = 0.150). This proportional stability in MT performance was consistent across all COVID-19 and MT hospitalization volumes strata, Table S3.

**Ischemic stroke/TIA and intracranial hemorrhage volumes**

The ischemic stroke/TIA admission volumes declined from 19,882 to 16,884 patients across the three months preceding versus the pandemic months, corresponding to a 15.1% (95%CI, −15.6 to −14.6, N = 113 sites) reduction with an adjusted mean (SE) number of ischemic stroke or TIA/month/center decreasing from 64.3 (6.8) to 55.6 (6.5) across the two epochs (p < 0.0001). Complete results are presented in Table S4.

The ICH admission volumes, submitted by 100 sites, decreased from 4002 to 3540 patients across the three months immediately before versus the pandemic months, representing an 11.5% (95%CI, −12.6 to −10.6) decline with the adjusted mean (SE) number of hospitalizations for ICH/month/center dropping from 13.4 (2.6) to 11.6 (2.6) across the two periods (p < 0.0001), Table S5.

**Changes in stroke care metrics during the pandemic as a function of COVID-19 hospitalization volumes**

Figures 1 and 2 provide the weekly volume of stroke admissions (ischemic and hemorrhagic), MT, and COVID-19 hospitalizations. COVID-19 hospital weekly volume data was available for 131 centers. There was an early peak of 1235 COVID-19 hospitalizations in February which predominantly originated from one hospital in Wuhan, China. Significant reductions in the mean monthly volumes were seen for all stroke care metrics across all tertiles of low, mid, and high COVID-19 hospitalization volumes. The exception was ICH volumes in high-volume COVID-19 centers which did not show a statistically significant difference (Tables 1, S4, and S5). High-volume COVID-19 centers (−20.5%; 95%CI, −22.6 to −18.6) had greater declines in MT volumes than mid- (−10.1%; 95%CI, −11.8 to −8.6; p < 0.0001) and low-volume (−8.7%; 95%CI, −10.7 to −7.1; p < 0.0001) COVID-19 centers, Table 2. Likewise, high-volume COVID-19 centers (−22.7%; 95%CI, −23.7 to −21.8) had greater reductions in stroke hospitalization volumes than mid- (−19.8%; 95%CI, −20.8 to −19.0; p < 0.0001) and low-volume (−12.6%; 95%CI, −13.4 to −11.9; p < 0.0001) COVID-19 centers, Table 1.

**Changes in stroke care metrics during the pandemic as a function of stroke center MT and admission volumes**

Significant declines in the mean monthly volumes were observed for all stroke/MT metrics across low-, mid-, and high-volume stroke/MT centers except MT volumes in low-volume MT centers showed a trend in decline (Tables 1, 2, S4, and S5). Mid-volume stroke centers (−17.6%; 95% CI, −18.5 to −16.7) demonstrated greater decreases in stroke admission volumes
than low-volume (−15.1%; 95% CI, −16.3 to −13.9; p < 0.0001) centers, Table 1.

**Secondary objective**

Table S6 depicts the volumes for overall stroke, ischemic stroke/TIA, ICH hospitalizations, and MT procedures during the first three months of the pandemic versus the corresponding period in the prior year. Compared to the prior year, there were significant declines in the monthly volumes for stroke and ischemic stroke/TIA admissions but not for ICH and MT.

**Associations between the diagnoses of COVID-19 and stroke**

There were 124 centers that reported patients with concomitant stroke (all subtypes) and SARS-CoV-2 infection. To reduce bias, 13 centers with no COVID-19 patients were excluded, leaving 111 eligible centers. A diagnosis of any stroke was present in 791 of 54,366 (1.45%; 95% CI 1.35–1.55) COVID-19 hospitalizations. There was geographic variation with incidences ranging from 0.43% (95% CI 0.08–2.38) in Oceania to 11.9% in South America (95% CI 10.05–14.03), Table S7. Conversely, 784 of the 20,250 (3.9%, 95% CI 3.61–4.14) overall stroke admissions were diagnosed with COVID-19 with proportions varying from 0.14% (95% CI 0.03–0.78) in Oceania to 8.93% in South America (95% CI 7.54–10.55), Table S8.

**Discussion**

We noted a significant global decline in all measured stroke care metrics in the current study including the numbers of mechanical thrombectomy procedures (−12.7%), overall stroke admissions (−19.2%), ischemic stroke/TIA admissions (−15.1%), and intracranial hemorrhage hospitalization volumes (−11.5%) during the COVID-19 pandemic as compared to the immediately preceding three months, confirming our primary hypothesis. Volume reductions were also seen in relation to the equivalent period in the prior year for stroke admissions and ischemic/TIA admissions. The intensity of the decline was more pronounced when comparing the pandemic period with the immediate three months prior than with the same months in 2019 (MT: 12.7% vs. 6.0%; stroke admissions: 19.2% vs. 12.0%). This followed our a priori expectations in face of the expansions in MT indications along with its progressive but gradual global implementation in developed and developing countries.17 Interestingly, despite the absolute decrease in MT volumes, the proportion of MT relative to stroke admissions remained stable during the pandemic. While at first glance this might suggest that the intra-hospital workflow was maintained, it is possible that this was not the case since one would actually expect an increase in the MT ratio relative to stroke admissions as many studies have now demonstrated that there was a preferential decline in patients presenting with milder strokes during the pandemic.4,11,18–20 The decreases in the amount of stroke care were noted across centers with high, mid, and low COVID-19 hospitalization burden and also across high, mid, and low volume stroke and MT centers. As hypothesized, centers with higher COVID-19 inpatient volumes suffered more declines. Contrary to our expectations, the declines in stroke hospitalizations and MT volumes were more profound in mid-(and high-) volume than low-volume stroke centers. This might be related to the fact that larger centers were more likely to become the preferred destination for COVID-19 referrals leading to capacity issues. Finally, we confirmed a broad geographic variation in the patterns of stroke care decline.

Our results align with recent reports emphasizing the collateral effects of the COVID-19 pandemic on stroke systems of care from China,10,18 Spain,3,19 Italy,21,22 France,9,23 Germany,12 Brazil,20 Canada,24 and United States;5,11,25,26 showing declines in the volumes for MT, IVT, and stroke hospitalizations over the pandemic (Table S9–11). Some of these studies also reported delays in hospital arrival times9,21 and treatment workflow.9,21 Our analysis adds to the growing literature regarding the collateral damage of COVID-19 on stroke care with the advantage of providing a broader global perspective. While the overall data clearly points to a significant reduction in the quantity of stroke care provided during the pandemic, it also depicts variations within and across the different regions reflecting the diversity in the epidemiology for COVID-19 as well as in the socio-cultural behaviors, healthcare logistics, and infrastructure encountered across the globe. Indeed, our study demonstrated important geographic variations in the proportional declines for both stroke hospitalization and MT volumes. Notably, our analysis may have underestimated the impact of geographic disparities in healthcare resources and related socio-economic factors as we only included thrombectomy capable centers which are known to have better infrastructure than the more commonly found primary stroke centers. Moreover, there was a higher geographic variation in the proportional decline for stroke hospitalization (Asia, −20.5%; North America, −20.6%; Europe, −11.2%; South America, −15.9%; Oceania, −11.6%; Africa, −48.1%) than mechanical thrombectomy (Asia, −9.8%; North America, −14.5%; Europe, −14.4%;
South America, −12.4%, Oceania, −9.4%; Africa, −21.2%) volumes. As seen in relation to the stability in the MT ratio relative to stroke admissions, this might have been related to the favored decline in milder strokes over the course of the pandemic.\textsuperscript{4,11,18–20} Given the growing evidence supporting the association between COVID-19 and thromboembolic events, it would be expected that the stroke incidence would rise at the precipice of the pandemic. Several factors may explain this paradoxical global decrease in stroke, MT, and ICH volumes observed in this study. As this decline in stroke volume was seen in centers with low or non-existent COVID-19 hospitalizations, hospital access due to the COVID-19 hospitalization burden was unlikely a major factor.\textsuperscript{12} As elective surgeries were canceled with the pandemic, a decrease in perioperative stroke may have played a role. It is also conceivable that the environmental situation of a lockdown, with improved patient behaviors or medication compliance, may be protective in decreasing vascular events.\textsuperscript{27} A reduction in exposure to other common viruses that may play a role in triggering vascular events may have also reduced stroke risk. However, it is unlikely that true incidence of stroke declined and more likely the behavioral and infrastructural changes related to the pandemic led to a reduction of admission of AIS patients, especially during the initial phases of public lockdown. Fear of contracting SARS-CoV-2 may have led many patients with milder stroke presentations to avoid seeking medical attention.\textsuperscript{4,11,18–20} Physical distancing measures may have prevented patients from the timely witnessing of a stroke.

Our subgroup of 111 centers including 54,366 COVID-19 hospitalizations is the largest sample reporting the concomitant diagnoses of stroke and SARS-CoV-2 infection to date. Our 1.45% stroke rate in COVID-19 hospitalizations is similar to the pooled incidence of 1.1–1.2% (range, 0.9–2.7%) of hospitalized COVID-19 patients.\textsuperscript{28,29} Some variations in the proportions are expected given the different definitions (all strokes vs. ischemic only) and populations involved (all hospitalized vs. severely infected only) across studies. We also provide a new perspective on this relationship by reporting an incidence of 3.9% (784/20,250) for SARS-CoV-2 infection across all stroke admissions among centers with documented COVID-19 hospitalization.

**Study strengths and limitations**

The strength of our study was the large volume of patients (n = 64,416) and a high number of centers (n = 187) contributing data from a diverse population across six continents and 40 countries. Our study contained centers with high and low COVID-19 hospitalization admissions, high and low stroke admission, and MT volumes, permitting the generation of multiple hypotheses and endpoints.

The limitations of this study were that the diagnosis of stroke/TIA/ICH, thrombectomy volume in some centers was obtained using hospital ICD administrative codes, and verification for accurate diagnosis was not universally undertaken. The centers contributing to these data have systems in place to track stroke admissions; thus, the relative changes in volume from this analysis are likely accurate. Details on patient-level data including demographics, stroke subtypes, and clinical outcomes were not collected as these were not the focus of the study. As with any other study, our data may underestimate true rates of concomitant SARS-CoV2 infection with a stroke diagnosis depending on the frequency of testing at each site and across the study period. The definition of the pandemic period was arbitrary since the outbreak started and peaked at different times at different locations. After adjustment for peak COVID-19 volume for each country and continent, the monthly volume declines were retained for all stroke metrics (stroke hospitalization, MT, ICH). As the penetration of MT remains limited in many countries,\textsuperscript{17} some geographic regions were not represented (i.e. central Africa). We did not collect data on the timing or intensity of social distancing policies including lockdown implementation across the different localities which likely played an important role in the reported stroke care decline. Finally, the sampling varied with the availability of complete data in each subset of the analysis.

**Summary**

There was a significant global decline in mechanical thrombectomy and stroke admissions over the three months studied during the pandemic. These decreases were seen regardless of COVID-19 admission burden, individual pre-pandemic stroke, and MT volumes. Thus, it is critical to expeditiously raise public awareness to prevent the additional healthcare consequences associated with the lack of stroke treatment. These findings can inform regional stroke networks preparedness\textsuperscript{29} in the face of a future pandemic or anticipated surge of COVID-19 cases in order to ensure that the access and quality of stroke care remains preserved despite the crises imposed by the continuous spread of the virus.

**Acknowledgements**

Patrick Nicholson, MD, Jasmine Johann, MSN, FNP-BC, Judith Clark, RN, Matt Metzinger, MBA, CPHQ, Jefferson, Kamini Patel, RN, MBA, Janis Gimnane, RN.
Disclosures
Dr Nguyen: Medtronic.
Dr Nogueira: Stryker; Cerenovus/Neuravi; Ceretrieve.
Dr Walker: Medtronic, Cerenovus.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs
Y Mansour  https://orcid.org/0000-0001-8814-6431
Zhongming Qiu  https://orcid.org/0000-0002-1622-9526
James E. Siegler  https://orcid.org/0000-0003-0287-3967
Laura Mechthouff  https://orcid.org/0000-0001-9165-5763
Omer Eker  https://orcid.org/0000-0002-5696-5368
Raoul Pop  https://orcid.org/0000-0003-4417-1496
Juan F Arenillas  https://orcid.org/0000-0001-7464-6101
Mahmoud Mohammaden  https://orcid.org/0000-0002-7393-9989
Simone Nagel  https://orcid.org/0000-0003-2471-6647
Madassir Farooqui  https://orcid.org/0000-0003-3697-5697
Ameer E. Hassan  https://orcid.org/0000-0002-7148-7616
Allan Taylor  https://orcid.org/0000-0002-2692-2068
Bertrand Lapergue  https://orcid.org/0000-0002-8993-2175
Bruce CV Campbell  https://orcid.org/0000-0003-6362-9433
Noel Van Horn  https://orcid.org/0000-0001-5764-1982
Ryoo Yamamoto  https://orcid.org/0000-0001-8585-9831
Takehiro Yamada  https://orcid.org/0000-0001-5196-1934
Yukako Yazawa  https://orcid.org/0000-0003-3891-0221
Jane Morris  https://orcid.org/0000-0001-5256-8165
Michael D Hill  https://orcid.org/0000-0002-6269-1543
Thang Nguyen  https://orcid.org/0000-0002-2810-1685

Authors
Raul G. Nogueira1,*, Mohamad Abdalkader2, Muhammed M. Qureshi3, Michael R. Franke4, Ossama Yassin Mansour5,*, Hiroshi Yamagami6, Zhongming Qiu7, Mehdi Farhoudi8, James E. Siegler9, Shadi Yagh9, Eytan Raz11, Nobuyuki Sakai12,13, Nobuyuki Ohara13,14, Michel Piotin14, Laura Mechthouff15, Omer Eker16, Vanessa Chalumeau17, Timothy J. Kleinig18, Raoul Pop19, Jianmin Liu20, Hugh S.Winters21, Xinjian Shang22, Alejandro Rodriguez Vasquez23, Jordi Blasco24, Juan F.Arenillas25, Mario Martinez-Galdamez26, Alex Brehm27, Marios-Nikos Psychogios28, Pedro Llyyk29, Diogo C.Haussen29, Alhamza R.Al-Bayati30, Mahmoud H. Mohammaden31, Luisa Fonseca32, M Luis Silva33, Francisco Montalverne34, Leonardo Remieri35, Salvatore Mangiafico36, Urs Fischer37, Jan Gralla38, Donald Frei39, Chandril Chugh40, Brijesh P.Mehta40, Simon Nagel40, Markus Mohlenbruch40, Santiago Ortega-Gutierrez41, Mudassir Farooqui42, Ameer E. Hassan42, Allan Taylor42, Bertrand Lapergue42, Arturo Consoli43, Bruce CV Campbell46, Malveeka Sharma47, Melanie Walker48, Noel Van Horn49, Jens Fiehler50, Huy Thang Nguyen50, Quoc T.Nguyen50, Daisuke Watanabe51, Hao Zhang52, Hyunh V. Le53, Viet Q. Nguyen54, Ruchir Shah55, Thomas Devine56, Priyank Khandelwal57, Italo Linfante58, Wazim Izzath59, Pablo M.Lavados60, Veronica V. Olavarrieta61, Gisele Sampaio Silva62, Anna Verena de Carvalho Sousa63, Jawad Kirmani64, Martin Bendszus65, Tatsuo Amano66, Ryoo Yamamoto66, Ryosuke Doijiri66, Naoki Tokuda66, Takehiro Yamada67, Tadashi Terasaki68, Yukako Yazawa69, Jane G. Morris70, Emma Griffin71, John Thornton71, Pascale Lavotte72, Charles Matouk72, Michael D. Hill74, Andrew M. Demchuk74, Monika Keller-Oberpfalzer75, Fadi Nahab76, Dorothea Altschul77, Anna Ramos-Pachón77, Natalia Pérez de la Ossa78, Raghid Kikano79, William Boisseau80, Gregory Walker81, Steve M. Cordina82, Ajit Puri83, Anna Luisa Kuhn84, Dheeraj Gandhi84, Pankajavalli Ramakrishnan85, Roberta Novakovic-White86, Alex Cheb87, Odysseas Kargiotis88, Alexandra Czap89, Alicia Zha89, Hesham E. Masoud90, Carlos Lopez90, David Ozretic91, Fawaz Al-Mufi92, Wenjie Zie93, Zhengzhou Yuan95, Wenguo Huang95, Jun Lu96, Vladimir Kalousek97, Romain Bourrier100, Romain Guile100, Steven Hets101, Hooman M. Al-Jehani102, Adel AlHazzani103, Elyar Sadeghi-Hokmabadi104, Mohamed Tel85, Jeremy Payne106, Jin Soo Lee106, Ji Man Hong107, Sung-Il Sohn107, Yang-ha Hwang108, Dong Hoon Shin109, Hong Gee Roh110, Rody Edgell111, Rakesh Khati112, Ainsley Smith113, Amer Malik114, David Liebeskind115, Nabeel Herial116, Pascal Jabbour116, Pedro Magalhaes117, Atilla Ozcan Ozdemir118, Ozlem Aykac119, Takeshi Uwatoko119, Tomohisa Demchuk120, Hisao Shimizu121, Yuri Sugirua122, Fumio Miyashita123, Hiroki Fukuda124, Kosuke Miyake125, Junsuke Shimbo126, Yusuke Sugimura127, Andre Beer-Furlan128, Krishna Joshi129, Luciana Catanese129, Daniel Giancante Abud130, Octavio Portes Neto131, Masoud Mehrpour132, Amal Al Hashmi133, Mahir Saqur134, Abdulrahman Mostafa135, Johanna T. Fifi136, Syed Hussaini137, Seby John137, Rishi Gupta137, Rotem Sivan-Hoffmann139, Anna Reznik139, Achmad Fidaus Sani140, Serdar Geyik141, Efe E, Anachlee Churojana142, Abderrezza Ghoreishi143, Mohammad Sadaatnia144, Ehsan Sharifipour145, Alice Ma146, Ken Faulkner146, Teddy Wu147, Lester Leeg148, Adel Malek149, Barbara Voetsch150, Ajay Wakhloo151, Rodrigo Riveria152, Danny Moises Barrientos Iman153, Aleksandra Pikula154, Vasileios-Arenios Lioutas155, Gotz Thomalla156, Lee Birnbaum157, Paolo Machi158, Gianmarco Bernava159, Mollie McDermott160, Dawn Kleinodler161, Ken Wong162, Mary S.Patterson163, Jose Antonio Fiorot164, Vikram Shah165, Maria Bernada166, Dawn Kleinodler167, Kevin F. Faulk168, Tingting Wu169, Lester Leeg170, Adel Malek171, Zhongming Qiu172, Congguo Yin173, Hongxing Han174, Ya Peng175, Wenhui Chen176, Roberto Crosa177, Michel Eli Fruditch178,
Caparros Zaidat Calabresi, Chang Y. Young, 218 Navdeep Sangha 207
Feliks Koyfman 200
Leticia C. Rebello 198
Hidekazu Yamazaki 86
Drs. Nogueira and Nguyen contributed equally to this article.

1Neurology, Grady Memorial Hospital, Emory University, Atlanta, Georgia, USA
2Radiology, Boston Medical Center, Boston University School of Medicine, Boston, USA
3Radiology, Radiation Oncology, Boston Medical Center, Boston University School of Medicine, Boston, USA
4Neurology, Grady Memorial Hospital, Emory University, Atlanta, Georgia, USA
5Neurology Department, Stroke and Neurointervention Division, Alexandria University Hospital, Alexandria University, Egypt
6Stroke Neurology, National Hospital Organization, Osaka National Hospital, Japan
7Neurology, Xinqiao Hospital of the Army Medical University, Chongqing, China
8Tabriz University, Iran
9Neurology, Cooper Neurological Institute, Cooper University Hospital, Camden, New Jersey, USA
10Neurology, Radiology, New York University School of Medicine, New York, USA
11Radiology, Neurology, New York University School of Medicine, New York, USA
12Neurosurgery, Kobe City Medical Center General Hospital, Kobe, Japan
13Neurology, Kobe City Medical Center General Hospital, Kobe, Japan
14Fondation Ophthalmologique Adolphe de Rothschild, France
15Neurologie, Hospices Civils de Lyon, France
16Neuroradiologie, Hospices Civils de Lyon, France
17Hôpital Bicêtre, Paris, France
18Royal Adelaide Hospital, Australia
19Hôpitaux Universitaires de Strasbourg, France
20Changhai Hospital, Shanghai, China
21Royal Prince Alfred Hospital, Sydney, Australia
22Yijishan Hospital of Wannan Medical College, China
23Neurology, Hospital Clinic de Barcelona, Spain
24Interventional Neuroradiology, Hospital Clinic de Barcelona, Spain
25Neurology, Hospital Clinico Universitario, Valladolid, Spain
26Interventional Neuroradiology, Hospital Clinico Universitario, Valladolid, Spain
27University Hospital Basel, Switzerland
28Clinica Sagrada Familia, Buenos Aires, Argentina
29Neurology, Grady Memorial Hospital, Emory University, Atlanta, Georgia, USA
30Stroke, Centro Hospitalar Universitário de São João, Portugal
31Neuroradiology, Centro Hospitalar Universitário de São João, Portugal
32Hospital Geral de Fortaleza, Brazil
33Careggi University Hospital, Florence, Italy
34Neurology, University Hospital Bern, Switzerland
35Interventional Neuroradiology, University Hospital Bern, Switzerland
36Swedish Medical Center, USA
37MAX Superspeciality Hospital, India
38Memorial Neuroscience Institute, Florida
39Neurology, University Hospital Heidelberg, Germany
40Neuroradiology, University Hospital Heidelberg, Germany
41Neurology, University of Iowa, USA
42Neurosciences, Valley Baptist Medical Center, Harlingen, Texas, USA
43Neurosurgery, University of Cape Town, South Africa
44Neurology, Hôpital Foch, France
45Interventional Neuroradiology, Hôpital Foch, France
46Royal Melbourne Hospital, Melbourne, Australia
47Neurology, University of Washington, Seattle, USA
48Neurosurgery, University of Washington, Seattle, USA
49Interventional Neuroradiology, Universitätsklinikum Hamburg-Eppendorf, Germany
50People’s 115 Hospital, Vietnam
51IMS Tokyo-Katsushika General Hospital, Japan
52Affiliated Hangzhou First People’s Hospital, China
53Hue Central Hospital, Vietnam
54Erlander Medical Center, USA
55Rutgers University, USA
56Miami Cardiac and Vascular Institute, USA
57Nottingham University Hospitals, United Kingdom
58Clínica Alemana, Universidad del Desarrollo, Chile
59Universidade Federal de Sao Paulo Hospital Israelita Albert Einstein, Brazil
60Hospital Israelita Albert Einstein, Brazil
61Hackensack Meridian Health, New Jersey, USA
62Neuroradiology, University Hospital Heidelberg, Germany
63Kyorin University, Japan 64 Yokohama Brain and Spine Center, Japan
Supplemental material
Supplemental material for this article is available online.

References
1. Zubair AS McAlpine LS Gardin T Farhadian S Kuruvilla DE and Spudich S. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol 2020; 77: 1018–1027.
2. Oxley TJ Mocco J Majidi S, et al. Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med 2020; 382: e60.
3. Rudilosso S Laredo C Vera V, et al. Acute stroke care is at risk in the era of COVID-19: experience at a comprehensive stroke center in Barcelona. Stroke 2020; 51: 1991–1995.
4. Yaghi S Iyshida K Torres J, et al. SARS-CoV-2 and stroke in a New York Healthcare System. Stroke 2020; 51: 2002–2011.
5. Onteddu SR Nalleballe K Sharma R and Brown AT. Underutilization of health care for strokes during the COVID-19 outbreak. Int J Stroke 2020; 15: NP9–NP10.
6. Varga Z Flammer AJ Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395: 1417–1418.
7. Connors JM and Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020; 135: 2033–2040.
8. Kansagra AP Goyal MS Hamilton S and Albers GW. Collateral effect of Covid-19 on stroke evaluation in the United States. N Engl J Med 2020; 383: 400–401.
9. Kerleroux B Fabacher T Bricout N, et al. Mechanical thrombectomy for acute ischemic stroke amid the COVID-19 outbreak: decreased activity, and increased care delays. Stroke 2020; 51: 2012–2017.
10. Zhao J Li H Kung D Fisher M Shen Y and Liu R. Impact of the COVID-19 epidemic on stroke care and potential solutions. Stroke 2020; 51: 1996–2001.
11. Siegler JE Heslin ME Thau L Smith A and Jovin TG. Falling stroke rates during COVID-19 pandemic at a comprehensive stroke center. J Stroke Cerebrovasc Dis 2020; 29: 104953.
12. Hoyer C Ebert A Huttner HB, et al. Acute stroke in times of the COVID-19 pandemic: a multicenter study. Stroke 2020; 51: 2224–2227.
13. Roman LS Menon BK Blasco J, et al. Imaging features and safety and efficacy of endovascular stroke treatment: a meta-analysis of individual patient-level data. Lancet Neurol 2018; 17: 895–904.
14. Nogueira RG Jadhav AP Haussen DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med 2018; 378: 11–21.
15. Albers GW Marks MP Kemp S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. *N Engl J Med* 2018; 378: 708–718.

16. Liao JN Chao TF Liu CJ, et al. Seasonal variation in the risk of ischemic stroke in patients with atrial fibrillation: a nationwide cohort study. *Heart Rhythm* 2018; 15: 1611–1616.

17. Martins SO Mont’Alverne F Rebello LC, et al. Thrombectomy for stroke in the public health care system of Brazil. *N Engl J Med* 2020; 382: 2316–2326.

18. Teo KC Leung WCY Wong YK, et al. Delays in stroke onset to hospital arrival time during COVID-19. *Stroke* 2020; 51: 2228–2231.

19. Montaner J Barragán-Prieto A Pérez-Sánchez S, et al. Break in the stroke chain of survival due to COVID-19. *Stroke* 2020; 51: 2307–2314.

20. Diegoli H Magalhães PSC Martins SCO, et al. Decrease in hospital admissions for transient ischemic attack, mild, and moderate stroke during the COVID-19 era. *Stroke* 2020; 51: 2315–2321.

21. Baracchini C Pieroni A Viaro F, et al. Acute stroke management pathway during coronavirus-19 pandemic. *Neurol Sci* 2020; 41: 1003–1005.

22. Morelli N Rota E Terracciano C, et al. The baffling case of ischemic stroke disappearance from the Casualty Department in the COVID-19 era. *Eur Neurol* 2020; 83: 213–215.

23. Pop R Quenardelle V Hasiu A, et al. Impact of the COVID-19 outbreak on acute stroke pathways - insights from the Alsace region in France. *Eur J Neurol* 2020; 27: 1783–1787.

24. Bullrich MB Fridman S Mandzia JL, et al. COVID-19: stroke admissions, emergency department visits, and prevention clinic referrals. *Can J Neurol Sci* 2020; 47: 693–696.

25. Schirmer CM Ringer AJ Arthur AS, et al; Endovascular Research Group (ENRG). Delayed presentation of acute ischemic strokes during the COVID-19 crisis. *J Neurointerv Surg* 2020; 12: 639–642.

26. Uchino K Kolikonka MK Brown D, et al. Decline in stroke presentations during COVID-19 surge. *Stroke* 2020; 51: 2544–2547.

27. American Heart Association’s Mission: Lifeline and Get With The Guidelines Coronary Artery Disease Advisory Work Group and the Council on Clinical Cardiology’s Committees on Acute Cardiac Care and General Cardiology and Interventional Cardiovascular Care*. Temporary Emergency Guidance to STEMI Systems of Care During the COVID-19 Pandemic: AHA’s Mission: Lifeline. *Circulation* 2020; 142: 199–202.

28. Tan YK Goh C Leow AST, et al. COVID-19 and ischemic stroke: a systematic review and meta-summary of the literature. *J Thromb Thrombol* 2020; 50: 587–595.

29. Nguyen TN Abdalkader M Jovin TG, et al. Mechanical thrombectomy in the era of the COVID-19 pandemic: emergency preparedness for neuroscience teams: a guidance statement from the Society of Vascular and Interventional Neurology. *Stroke* 2020; 51: 1896–1901.